Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP04459
- Development stage
- Unknown
- Lead developer
- Risen
01
Overview
RP04459: sourced facts only. name: "The identification of RP04459 as a selective ADAR1 inhibitor underscores its potential to enhance immune-based therapies for cancers reliant on ADAR1 activity." [DOI:10.1158/1538-7445.am2025-4288]; target: "The identification of RP04459 as a selective ADAR1 inhibitor underscores its potential to enhance immune-based therapies for cancers reliant on ADAR1 activity." [DOI:10.1158/1538-7445.am2025-4288]; developer: "Risen Pharmaceuticals Private Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2025-4288]
02
Targets
ADAR (Adenosine deaminases acting on RNA (ADAR) family)
Beyond the preview
Go deeper on RP04459.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP04459.